Posibil6eskd: Cardiovascular Outcome Study Of Csl300 (Clazakizumab) In Subjects With End Stage Kidney Disease On Dialysis
Posted Date: Apr 19, 2024
- Investigator: Jwalant Modi
- Specialties: Kidney Disease, Nephrology
- Type of Study: Drug
CSL 300 (clazakizumab) is an IL-6 monoclonal antibody that is being developed to reduce the risk of cardiovascular events in patients on dialysis, a population with high rates of cardiovascular disease. The study drug will be given through the dialysis tubing once a month while on dialysis, and blood work will be collected at treatments as well. The study will be collecting "end points", which are cardiovascular events, and is expected to last for about 5 years. All study procedures and medication will be given in the DCI dialysis clinics (select locations).
Criteria:
Subjects Must Be Able To Consent And Have Been On Dialysis For At Least 12 Weeks. Subjects Must Have Either Diabetes Or A History Of Cardiovascular Disease, Or Peripheral Vascular Disease. Subjects Cannot Have Current Infection, Gangrene, Recent Cardiovascular Event Or Prior Gastric Bypass Surgery. Subjects Must Be Compliant With Dialysis Treatments And Medications. Other Criteria Will Also Apply.
Keywords:
Dialysis, Cardiovascular, Kidney
For More Information:
Heather Duncan
513-559-3362
heather.duncan@uc.edu